STOCK TITAN

Aura Biosciences Inc - AURA STOCK NEWS

Welcome to our dedicated news page for Aura Biosciences (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aura Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aura Biosciences's position in the market.

-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.89%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.73%
Tags
none
Aura Biosciences Inc

Nasdaq:AURA

AURA Rankings

AURA Stock Data

359.40M
30.96M
7.69%
83.26%
4.94%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boston

About AURA

at aura biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. by safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. our lead program in ocular melanoma (om), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. the goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. by enabling physicians to treat cancer mo